Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections.
Ticarcillin-clavulanate is active in vitro against the vast majority of pathogens involved in skin and soft tissue infections. A compilation of six controlled clinical trials of ticarcillin-clavulanate for treatment of skin infections showed a satisfactory clinical response in 175 (93%) of 189 cases. The bacteriologic response included eradication of Staphylococcus aureus, Enterococcus species, Enterobacteriaceae, and Pseudomonas aeruginosa in 88%, 75%, 88%, and 77% of cases, respectively. In addition, the records of 17 patients with diabetic foot infections who were treated with ticarcillin-clavulanate as monotherapy in controlled trials are reviewed. Eight of these infections were cured and eight were improved at the end of therapy. The available clinical data suggest that ticarcillin-clavulanate is effective antimicrobial therapy for skin infections.
Service of Infectious Disease, Akron City Hospital, Ohio.
T M
TM
File
J S
JS
Tan
D000038:Abscess / Q000188:drug therapy; D001424:Bacterial Infections / Q000188:drug therapy*; D002481:Cellulitis / Q000188:drug therapy*; D002969:Clavulanic Acids / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D012883:Skin Ulcer / Q000188:drug therapy; D013982:Ticarcillin / Q000627:therapeutic use*; D014946:Wound Infection / Q000188:drug therapy; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D065093:beta-Lactamase Inhibitors; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin